SynthesisDrug design, development and therapy2017
Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies.
Synthesis in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.Pharmacology research & perspectives · 2020Pooled it
- Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis.European journal of clinical pharmacology · 2020Pooled it
- The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.International urology and nephrology · 2018Pooled it
- Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.Digestive diseases and sciences · 2017Pooled it
- A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes.Nature communications · 2023Trial
- Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.Journal of gastroenterology · 2023Trial
- Kidneys on the Frontline: Nephrologists Tackling the Wilds of Acute Kidney Injury in Trauma Patients-From Pathophysiology to Early Biomarkers.Diagnostics (Basel, Switzerland) · 2025Review
- Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.Clinical pharmacokinetics · 2025Review
- Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis.Biomedicines · 2024Review
- Review
- Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort.BMC nephrology · 2023Article
- Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review.Advances in therapy · 2023Review
- Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.Chonnam medical journal · 2023Review
- A Meta-Analysis of Proton Pump Inhibitor Use and the Risk of Acute Kidney Injury: Geographical Differences and Associated Factors.Journal of clinical medicine · 2023Article
- Colorectal Surgery in Critically Unwell Patients: A Multidisciplinary Approach.Clinics in colon and rectal surgery · 2022Review
- Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review.Therapeutic advances in gastroenterology · 2022Review
- Article
- Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.Clinical and experimental nephrology · 2021Article
- Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.British journal of clinical pharmacology · 2021Article
- Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have suggested a potential increased risk of acute kidney injury (AKI) among proton-pump inhibitor (PPI) users. However, the present results are conflicting. Thus, we performed a meta-analysis to investigate the association between PPI therapy and the risk of AKI.
methodsEMBASE, PubMed, Web of Science, and Cochrane Library databases (up to September 23, 2016) were systematically searched for any studies assessing the relationship between PPI use and risk of AKI. Studies that reported relevant risk ratios (RRs), odds ratios, or hazard ratios were included. We calculated the pooled RRs with 95% confidence intervals (CI) using a random-effects model of the meta-analysis. Subgroup analysis was conducted to explore the source of heterogeneity.
resultsSeven observational studies (five cohort studies and two case-control studies) were identified and included, and a total of 513,696 cases of PPI use among 2,404,236 participants were included in the meta-analysis. The pooled adjusted RR of AKI in patients with PPIs use was 1.61 (95% CI: 1.16-2.22;
conclusionPPI use could be a risk factor for AKI and should be administered carefully. Nevertheless, some confounding factors might impact the outcomes. More well-designed prospective studies are needed to clarify the association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.